title: Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Survival Results From STAMPEDE (NCT00268476).
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D000068579:Celecoxib / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage; D004164:Diphosphonates / Q000008:administration & dosage; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D008297:Male; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D019233:Retreatment; D016896:Treatment Outcome; D000077211:Zoledronic Acid
chemical_list: D014408:Biomarkers, Tumor; D050071:Bone Density Conservation Agents; D052246:Cyclooxygenase 2 Inhibitors; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D000068579:Celecoxib